Literature DB >> 35819694

Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model.

Qiangyuan Tian1, Hua Yin2, Jisen Li2, Jinggong Jiang2, Binbin Ren2, Junhui Liu2.   

Abstract

In recent years, the medical field had significantly progressed to a greater extent which was evidenced with increased life expectancy and decreased mortality rate. Due to the growth of medical field, numerous communicable diseases are prevented and eradicated, whereas the non-communicable disease incidence has been increased globally. One such non-communicable disease which threatens the global population is stroke. Stroke tends to be the second leading cause of death and disability in older population. In lower- and middle-income countries, increased incidence rate of stroke was also evidenced in younger population which is alarming. Lifestyle changes, poor physical activity, stress, consumption of alcohol, oral contraception, and smoking tend to be the causative agents of stroke. Since thrombus formation is the major pathology of stroke, drugs were targeted to thrombolysis. Currently thrombolytic, antiplatelet, and anticoagulant therapies were given for the stroke patients. But the recovery rate of stroke patients with available drugs is very slow. Hence, it is a need of today to discover a drug with increased recovery rate and decreased or nil side effects. Phytochemicals are the best options to treat such non-communicable chronic diseases. Visnagin is one such compound which is used to regulate blood pressure, treat kidney stones, tumors of bile duct, renal colic, and whooping cough. It possesses anti-inflammatory, neuroprotective, and cardioprotective properties; it was also proven to treat epileptic seizures. In this study, the anti-ischemic effect of a furanochrome visnagin was assessed in in vivo rat model. Middle cerebral ischemic/reperfusion was induced in healthy male Sprague Dawley rats and treated with different concentrations of visnagin. The neuroprotective effect of visnagin against cerebral ischemia-induced rats was assessed by analyzing the neurological score, brain edema, infract volume, and Evans blue leakage. The anti-inflammatory property of visnagin was assessed by quantifying proinflammatory cytokines in serum and brain tissues of cerebral ischemia-induced rats. Prostaglandin E-2, COX-2, and NFκ-β were estimated to assess the anti-ischemic effect of visnagin. Histopathological analysis with H&E staining was performed to confirm the neuroprotective effect of visnagin against cerebral ischemia. Our results authentically confirm that visnagin has prevented the inflammation in brain region of cerebral ischemia-induced rats. The neurological scoring and the quantification of PGE-2, COX-2, and NFκ-β prove the anti-ischemic effect of visnagin. Furthermore, the histopathological analysis of hippocampal region provides evidence to the neuroprotective effect of visnagin against cerebral ischemia. Overall, our study confirms visnagin as a potent alternative drug to treat stroke.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anti-inflammatory; Anti-ischemic; Cerebral ischemia/reperfusion; In vivo model; Neuroprotectant; Stroke

Year:  2022        PMID: 35819694     DOI: 10.1007/s12010-022-04009-0

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   3.094


  29 in total

Review 1.  Global Burden of Stroke.

Authors:  Mira Katan; Andreas Luft
Journal:  Semin Neurol       Date:  2018-05-23       Impact factor: 3.420

Review 2.  Epidemiology, aetiology, and management of ischaemic stroke in young adults.

Authors:  Merel S Ekker; Esther M Boot; Aneesh B Singhal; Kay Sin Tan; Stephanie Debette; Anil M Tuladhar; Frank-Erik de Leeuw
Journal:  Lancet Neurol       Date:  2018-09       Impact factor: 44.182

3.  Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.

Authors:  Esther Parada; Ana I Casas; Alejandra Palomino-Antolin; Vanessa Gómez-Rangel; Alfonso Rubio-Navarro; Victor Farré-Alins; Paloma Narros-Fernandez; Melania Guerrero-Hue; Juan Antonio Moreno; Juliana M Rosa; José M Roda; Borja J Hernández-García; Javier Egea
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

Review 4.  Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective.

Authors:  Paul A Lapchak
Journal:  Expert Opin Investig Drugs       Date:  2011-01       Impact factor: 6.206

Review 5.  Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2014-04-26       Impact factor: 7.616

6.  Mitigation of murine focal cerebral ischemia by the hypocretin/orexin system is associated with reduced inflammation.

Authors:  Xiaoxing Xiong; Robin E White; Lijun Xu; Liya Yang; Xiaoyun Sun; Bende Zou; Conrado Pascual; Takeshi Sakurai; Rona G Giffard; Xinmin Simon Xie
Journal:  Stroke       Date:  2013-01-24       Impact factor: 7.914

Review 7.  The incidence of all stroke and stroke subtype in the United Kingdom, 1985 to 2008: a systematic review.

Authors:  Prachi Bhatnagar; Peter Scarborough; Nigel C Smeeton; Steven Allender
Journal:  BMC Public Health       Date:  2010-09-08       Impact factor: 3.295

8.  β-arrestin 2 negatively regulates NOD2 signalling pathway through association with TRAF6 in microglia after cerebral ischaemia/reperfusion injury.

Authors:  Lin Chen; Lingjun Kong; Xinbing Wei; Yimeng Wang; Bing Wang; Xiumei Zhang; Jinpeng Sun; Huiqing Liu
Journal:  J Cell Mol Med       Date:  2019-02-22       Impact factor: 5.310

Review 9.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.

Authors:  Jonathan Emberson; Kennedy R Lees; Patrick Lyden; Lisa Blackwell; Gregory Albers; Erich Bluhmki; Thomas Brott; Geoff Cohen; Stephen Davis; Geoffrey Donnan; James Grotta; George Howard; Markku Kaste; Masatoshi Koga; Ruediger von Kummer; Maarten Lansberg; Richard I Lindley; Gordon Murray; Jean Marc Olivot; Mark Parsons; Barbara Tilley; Danilo Toni; Kazunori Toyoda; Nils Wahlgren; Joanna Wardlaw; William Whiteley; Gregory J del Zoppo; Colin Baigent; Peter Sandercock; Werner Hacke
Journal:  Lancet       Date:  2014-08-05       Impact factor: 79.321

Review 10.  Stroke in young adults: Current trends, opportunities for prevention and pathways forward.

Authors:  Tamer Yahya; Mohammad Hashim Jilani; Safi U Khan; Reed Mszar; Syed Zawahir Hassan; Michael J Blaha; Ron Blankstein; Salim S Virani; Michelle C Johansen; Farhaan Vahidy; Miguel Cainzos-Achirica; Khurram Nasir
Journal:  Am J Prev Cardiol       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.